铁蛋白激酶MET在骨髓瘤瘤中的治疗潜力
Ming Zeng1, Can Liu2, Haoli Gong1
1Department of Pediatric Orthopedics, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.
Frontiers in molecular biosciences
|April 10, 2024
概括
对于转移性患者来说,骨髓瘤治疗仍然具有挑战性. 针对MET途径对癌症进展至关重要,为骨髓瘤提供了一个有前途的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 骨髓瘤是一种主要的骨癌,在儿童和年轻人中普遍存在.
- 目前的治疗方法对转移性骨髓瘤的成功程度有限.
- 最近的研究强调了MET途径在癌症进展中的作用.
研究的目的:
- 审查三十年来关于MET在骨髓瘤中的参与的研究.
- 探索MET作为骨髓瘤的潜在治疗点.
主要方法:
- 关于MET和骨髓瘤的研究的文献综述.
- 分析MET在癌症生长,入侵,转移和耐药性方面的作用.
主要成果:
- HGF/MET通路与骨髓瘤的进展有关.
- MET信号传递对癌症生长和各种癌症转移至关重要.
- 在其他癌症中,MET是经过验证的目标,目前正在进行临床试验.
结论:
- MET代表了骨髓瘤的一个重要的治疗点.
- 针对HGF/MET途径可能会改善骨髓瘤患者的治疗结果.
- 对MET向治疗骨髓瘤的进一步研究是有必要的.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Receptor Tyrosine Kinases
12.8K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.8K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K


